Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 6OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 51Multiple Myeloma 42Lymphoma 42Neoplasm Metastasis 41Lung Neoplasms 38Breast Neoplasms 38Prostatic Neoplasms 32Carcinoma, Non-Small-Cell Lung 31Leukemia, Myeloid, Acute 30Colorectal Neoplasms 28Melanoma 27Ovarian Neoplasms 26Hematologic Neoplasms 24Pancreatic Neoplasms 22Urinary Bladder Neoplasms 21Lymphoma, Non-Hodgkin 21Glioma 21Carcinoma, Renal Cell 19Sarcoma 18Myelodysplastic Syndromes 16Burkitt Lymphoma 16Triple Negative Breast Neoplasms 15Stomach Neoplasms 15Neuroblastoma 14Colonic Neoplasms 14Brain Neoplasms 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Lymphoma, Large B-Cell, Diffuse 13Leukemia, Lymphocytic, Chronic, B-Cell 13Fallopian Tube Neoplasms 13

Interventions

tivozanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Hereditary Sensory and Autonomic Neuropathies × 30 days × Clear all
NCT04645160 2026-06-03

Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
31 enrolled
Gastrointestinal

Bile Duct Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡